Phase 2 N=8 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
Lymphoma · Non-Hodgkin Lymphoma · NHL
Primary: Phase 2: Complete Response (CR) Rate
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=52 A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Change From Baseline Ocular Itching Score on High Pollen Days — -0.65; 0.16; -0.69 units on a scale
Phase 2 N=415 Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)
Advanced Solid Tumors
Primary: Percentage of Participants With ≥1 Dose Limiting Toxicity (DLT) — 0.0; 13.3; 0.0; 7.5 Percentage of Participants
Phase 2 N=100 Practical Anemia Bundle for SusTained Blood Recovery
Anemia · Critical Illness
Primary: Hemoglobin Concentrations — 11.5; 12.2 g/dL — p=0.02
Phase 2 N=35 AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)
NSCLC Stage IV
Primary: Objective Response Rate (ORR) — 6 Participants
Phase 2 N=35 Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression
Major Depression
Primary: Hamilton Depression Rating Scale (HAM-D) Effect Seven Days After Dosing (D7) — 16.92; 9.72 score on a scale
Phase 2 N=75 Priming Immunotherapy in Advanced Disease With Radiation
Non-small Cell Lung Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Proportion of Participants Alive and Without Progression — .66 proportion of participants
Phase 2 N=52 NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment
Mild Cognitive Impairment
Primary: Cognitive Scores at Baseline and Week 12 — 96; 99; 101; 103 score on a scale
Phase 2 N=60 Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)
Treatment-Resistant Depression
Primary: Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score 24 Hours (Day 2) After Injection — -14.1; -11.4; -8.4; -8.9 Scores on a Scale
Phase 2 N=8 Gene Therapy for Wiskott-Aldrich Syndrome
Wiskott-Aldrich Syndrome (WAS)
Primary: Safety of Reduced Conditioning Regimen — 8 Participants
Phase 2 N=229 A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Primary: Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 — 13.6; 6.8; 21.7; 17 percentage of…
Phase 2 N=50 Dietary Counselling Plus Omega-3 Supplementation in the Treatment of Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Feasibility of Participant Recruitment and Intervention Delivery — 8; 8 months
Phase 2 N=30 Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC)
Primary: Number of Patients Treated in Compliance With Protocol — 29 Participants
Phase 2 N=171 Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)
Relapsed or Refractory Peripheral T Cell Lymphoma
Primary: Part B: CT-based Objective Response Rate (ORR) by Independent Review Committee (IRC) — 43.1 percentage of participants — p=<0.0001
Phase 2 N=20 Controlled Trial of Panhematin in Treatment of Acute Attacks of Porphyria
Acute Porphyrias
Primary: Difference in NRS Pain Score Between Baseline and 12 Hours — -0.2; -0.2 score on a scale